A group of directors of hospitals and clinics from Kazakhstan visited Poland. Guests familiarized themselves with the functioning of health care facilities at various levels. Presentations were organized in the office of Polpharma, which, thanks to its investments in Kazakhstan, under the Santo brand, is a leading producer on that market.
The delegation included directors and officers from several municipal hospitals, polyclinics and specialized health facilities in Kazakhstan. The program of stay in Poland included a visit to Biała Podlaska, where the guests got acquainted with the organization and operation of the Provincial Specialist Hospital, including the use of IT tools, experience in the field of outsourcing and cooperation with the NFZ. They also visited Lublin, where they met with the staff of several hospitals there, including University Children's Hospital, experts from the University of Economics and Innovation, as well as study visits in the poviat counseling and family clinic in Dąbrowice / Lipniaki.
During their stay in Warsaw, Kazakh directors were shown, among others, principles of creating a Hospital Receptacle and optimizing patient therapy in closed care, including the selection of basic and supplementary medicines in medical procedures; pharmaco-economics and financing of medicines in hospitals. The program also includes the functioning of the rescue system in Poland: from the legislative basics, through organization on a national scale, the composition of emergency teams, qualifications of rescuers and doctors, to services cooperating with the system and examples of specialized hospital units, e.g. hemodynamic laboratories, toxicology departments and burns treatment. As part of a visit to the capital, guests visited the Central Clinical Hospital at Banacha Street in Warsaw and the Center for Comprehensive Rehabilitation in Konstancin, where they became acquainted with the services in the field of orthopedic surgery and rehabilitation.
Presentations for guests were organized in the Warsaw office of the Polpharma company, which thanks to its investments in Kazakhstan, under the Santo brand, became a leading producer on the market, with a portfolio of over 260 generic and original drugs in 12 pharmacotherapeutic groups. In 2013, she invested in a plant in Szymek, located in the south of Kazakhstan, making its modernization, under which, among others, a new ampoule, new powder and high storage warehouse. Currently, the company is continuing the project, worth approximately USD 100 million, including the modernization of production in accordance with international GMP standards. In 2013, Santo Member of Polpharma Group also won the title of "Best producer of goods for the population of Kazakhstan" in the category of large enterprises.
